Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Phase 2 Completed 1 enrolled University Health Network, Toronto

NaSingle-groupOpen-labelTreatment

Summary

This is a single participant study of decidual stromal cells (DSC) for the treatment of steroid refractory graft-versus-host disease (GVHD) in a patient with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN).

Timeline

Start: 2021-03-11
Primary completion: 2021-06-09
Completion: 2021-06-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Decidual Stromal Cells	Cell therapy	1e+06 cells/kg	Intravenous

Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Summary

Timeline

Drugs

Indications